Amidst a backdrop of global economic challenges and shifting trade dynamics, Asian markets have been navigating a complex landscape. For investors considering alternatives to the major indices, penny stocks—often representing smaller or newer companies—remain an intriguing option. While the term "penny stock" might seem outdated, these investments can still offer substantial opportunities when backed by strong financial health and potential for growth.
Operating results put Cathay Pacific Airways (SEHK:293) in focus
Cathay Pacific Airways (SEHK:293) has attracted fresh attention after reporting December 2025 and full year traffic figures, with double digit year on year growth in both passenger volumes and cargo tonnage.
See our latest analysis for Cathay Pacific Airways.
The HK$12.58 share price has been supported by an 11.72% 90 day share price return and a 27.65% 1 year total shareholder return, suggesting momentum has been building...
Why East Buy Holding (SEHK:1797) is in focus ahead of earnings
East Buy Holding (SEHK:1797) is drawing attention as it heads into its 28 January 2026 earnings release, with investors closely watching revenue growth, margin trends and management guidance.
See our latest analysis for East Buy Holding.
At a share price of HK$23.08, East Buy Holding has recently seen a 27.73% 1 month share price return and a 44.97% 1 year total shareholder return. However, the 3 year total shareholder return of a...
In recent research released before 26 January 2026, Citi and UOB Kay Hian highlighted that China Overseas Land & Investment faces expected profit margin pressure, deeper write-offs, and weaker 2025 earnings across China’s stressed real-estate sector.
At the same time, both brokers continued to single out China Overseas Land & Investment as one of the relatively stronger developers within a sector undergoing restructuring and impairment-driven reset.
We’ll now examine how this combination of...
CStone Pharmaceuticals (SEHK:2616) has moved to refresh its governance and incentive structure, pairing a large equity award package for director and staff with board changes that bring new financial expertise and committee leadership.
See our latest analysis for CStone Pharmaceuticals.
These governance moves come as CStone’s share price trades at HK$5.43, with a 1-year total shareholder return of 132.05% contrasting with a 5-year total shareholder return of 52.03% and a softer 90-day share...
In January 2026, Shanghai Fudan Microelectronics Group issued unaudited guidance for 2025, expecting revenue of about RMB 3,930,000,000 to RMB 4,030,000,000, but projecting net profit attributable to shareholders to fall to roughly RMB 190,000,000 to RMB 283,000,000 and core net profit after non-recurring items to RMB 125,000,000 to RMB 185,000,000.
The company links this profit compression to inventory impairment after earlier stockpiling, higher research and development expenses from...
Crystal International Group recently announced plans to acquire a large industrial land parcel in Egypt for about US$30.40 million to build new production plants and supporting facilities, subject to local government approval.
This move signals a push to broaden its manufacturing footprint, reduce exposure to concentrated geopolitical and trade-policy risks, and offer global customers more flexible sourcing options.
We will now examine how this planned Egypt expansion, aimed at diversifying...
As global markets navigate a period of volatility and geopolitical uncertainty, the Asian market continues to present intriguing opportunities for investors, particularly in the realm of growth companies with high insider ownership. In this environment, stocks that demonstrate robust earnings growth and strong insider commitment can offer a compelling mix of potential stability and upside, making them noteworthy considerations for those looking to understand current trends in Asia's evolving...
OSL Group has issued earnings guidance indicating a net loss from continuing operations of HK$370 million to HK$430 million for FY2025, compared with a profit of about HK$55 million in FY2024, driven by higher expansion costs, fair value losses on digital assets and one-off professional fees.
Despite the loss guidance, the group forecasts IFRS income from its digital assets and blockchain platform business to rise to HK$450 million–HK$530 million and adjusted non-IFRS income to HK$490...